BioCentury
ARTICLE | Company News

Exelixis falls on delayed cobimetinib NDA review

July 2, 2015 12:47 AM UTC

Exelixis Inc. (NASDAQ:EXEL) was off $0.27 to $3.49 on Wednesday after FDA pushed back the PDUFA date for melanoma therapeutic cobimetinib to Nov. 11 from Aug. 11.

Exelixis said FDA changed the date after Exelixis' partner, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), submitted additional analyses requested by the agency of previously submitted data from the Phase III coBRIM trial. ...